School of Medicine
Showing 261-270 of 502 Results
-
Lu Tian
Professor of Biomedical Data Science and, by courtesy, of Statistics
Current Research and Scholarly InterestsMy research interest includes
(1) Survival Analysis and Semiparametric Modeling;
(2) Resampling Method ;
(3) Meta Analysis ;
(4) High Dimensional Data Analysis;
(5) Precision Medicine for Disease Diagnosis, Prognosis and Treatment. -
Robert Tibshirani
Professor of Biomedical Data Science and of Statistics
Current Research and Scholarly InterestsMy research is in applied statistics and biostatistics. I specialize in computer-intensive methods for regression and classification, bootstrap, cross-validation and statistical inference, and signal and image analysis for medical diagnosis.
-
George F Tidmarsh
Adjunct Professor, Pediatrics - Neonatology
BioDr. Tidmarsh received M.D. and Ph.D. from Stanford University, where he also completed fellowship training in Pediatric Oncology and Neonatology and is currently Adjunct Faculty of Pediatrics and Neonatology. He served as clinical faculty at Stanford for a number of years after fellowship prior to devoting his full time to clinical research and development in order to bring new treatments through the FDA approval process. Dr. Tidmarsh was President, Chief Executive Officer, Secretary and a Director of La Jolla Pharmaceutical Company from January 2012 until November 2019. While at La Jolla, Dr. Tidmarsh helped discover the use of angiotensin II for the treatment of shock and led all aspects of the development including approval by the US FDA and the EMA for the treatment of patients suffering from distributive shock. He also led the development of artesunate for the treatment of severe malaria, now FDA approved. Dr. Tidmarsh has over 30 years of experience in biotechnology, including the successful clinical development of 6 FDA-approved drugs. He previously served as the Founder and Chief Executive Officer of Horizon Pharma, Inc., a company he founded in 2005. While at Horizon, he led all aspects of development of Duexis, which was approved by the FDA for the treatment of rheumatoid arthritis. In 2022, Horizon was sold to Amgen for $28B. He also founded Threshold Pharmaceuticals, Inc. and held senior positions at Coulter Pharmaceutical, Inc. (acquired by GlaxoSmithKline) and SEQUUS Pharmaceuticals, Inc. (acquired by Johnson & Johnson). While at Coulter and SEQUUS, Dr. Tidmarsh led the clinical development of BEXXAR and Doxil, respectively, two FDA-approved anti-cancer agents.
At Stanford, Dr. Tidmarsh is devoted to teaching clinical research and development to residents, fellows and junior faculty. He founded and taught the Masters in Translational Research and Applied Medicine, one of the only translational medicine programs at Stanford. In addition, he is working to help improve the quality of medical care through various efforts which include serving on the board of Lucile Packard Foundation for Children's Health, as co-Director of the Drug Device Development Program he started in 2017 and as a Senior Advisor for the Center for Pediatric and Perinatal Education (CAPE). He focuses most of his efforts currently on improving scientific data integrity in published literature. -
Seda Tierney
Professor of Pediatrics (Cardiology)
Current Research and Scholarly InterestsAssessment of vascular health in children by non-invasive modalities
Exercise interventions in children with congenital and acquired heart disease
Use of telehealth to deliver interventions to children with congenital and acquired heart disease
Parentally-acquired echocardiograms
Quality Improvement in Pediatric Echocardiography
Echocardiography and outcomes in congenital heart disease
